Investigational drug · Phase 2
VMD-102
Also called: Single agent
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VMD-102"
First trial start
2026
Jul 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VMD-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma (HCC)
- Metastatic Uveal Melanoma
- Renal Cell Carcinoma (RCC)
- Nonsmall Cell Lung Cancer
- Colorectal Cancer (CRC)
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Melanoma · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "VMD-102" as an intervention, largest first.
VM Discovery, Inc.Industry
NCT07636785 · 111 participants (planned) · Start Jul 16, 2026 · Primary completion May 2031
Drug: VMD-102 · For: Hepatocellular Carcinoma (HCC); Metastatic Uveal Melanoma; Renal Cell Carcinoma (RCC) and 2 more
Sites: Scottsdale, Arizona; Los Angeles, California
Newest research
PubMed records naming it or its code names, newest first.
- Engineering extracellular vesicles for multi-cargo co-delivery in silicosis and related fibrotic diseases: design strategies and translational prospects.
Chen Z, Liu Y, Yang S, et al. · Biomaterials 2027
- A multi-omics study with in vitro and in vivo interventions targeting the leptin-mediated Hypoxia-Inducible Factor-1 Alpha metabolic-inflammatory axis in gastroesophageal reflux disease.
Wang Z, Zhang Q, Wufuer A, et al. · Biochim Biophys Acta Mol Basis Dis 2027
- Nisin Z and cinnamaldehyde co-delivery via fiber-reinforced alginate hydrogels: A synergistic in vitro strategy against infected pressure ulcers.
Fernandes J, Gomes M, Bastos ARC, et al. · Biomater Adv 2027
- Collaborative-adversarial jailbreaking: A propagation-aware attack framework for multi-agent code generation systems.
Qu Z, Geng M, Mao Y, et al. · Neural Netw 2027
- Icaritin enhances the anti-leukemic activity of imatinib in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia cells: functional involvement of PI3K/AKT signaling.
Tan G, Wang S, Qi L, et al. · Hematology 2026
- Adaptive kinase signaling enables escape from small molecule inhibition in glioblastoma.
van Heumen M, Hoosemans L, Piepers J, et al. · Cancer Biol Ther 2026
Also in development for Hepatocellular Carcinoma (HCC)
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- IBI310Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.